Pharming Group N.V annual ebitda
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V EBITDA Growth & History (PHAR)
Pharming Group N.V's calculated EBITDA was $33.8M for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $33.8M | $34.6M | — |
| 2024 | 2024-12-31 | −$848,000 | −$2.8M | — |
| 2023 | 2023-12-31 | $2.0M | −$22.2M | −91.81% |
| 2022 | 2022-12-31 | $24.1M | $4.2M | +21.05% |
| 2021 | 2021-12-31 | $20.0M | −$62.4M | −75.76% |
| 2020 | 2020-12-31 | $82.3M | $9.1M | +12.38% |
| 2019 | 2019-12-31 | $73.2M | — | — |
Pharming Group N.V quarterly ebitda
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.8M | −$1.0M | −10.55% |
| Q1 2026 | 2026-03-31 | $1.1M | — | — |
| Q4 2025 | 2025-12-31 | $9.4M | — | — |
| Q3 2025 | 2025-09-30 | $23.4M | — | — |
| Q2 2025 | 2025-06-30 | $9.8M | — | — |
Pharming Group N.V ebitda trends
Over the last five fiscal years, Pharming Group N.V's ebitda decreased from $82.3M to $33.8M, a change of −$48.5M. The latest reported quarter, Q2 2026, shows $8.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming secures priority review for lower-dose pediatric Joenja
Pharming ($PHAR) said the FDA accepted its supplemental application for a lower-dose Joenja formulation and granted priority review. The proposed expansion addresses patients aged four and older with activated PI3K delta syndrome who weigh ...
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...
